BAAM
ICPT

Baker Avenue Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Baker Avenue Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,000
Closed -$237K – 298
2014
Q3 		$237K Buy
+1,000
New +$255K 0.03% 235

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Baker Avenue Asset Management's ICPT Position: Q4 2014 in Review

Baker Avenue Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2014, closing a stake of 1,000 shares — an estimated $237K sold.

Baker Avenue Asset Management first reported a position in ICPT in Q3 2014 and held it in 1 quarter. The position peaked at $237K in Q3 2014. 169 funds tracked by Wall St. Rank hold ICPT as of Q4 2014.

  • Baker Avenue Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Baker Avenue Asset Management sold 1,000 Intercept Pharmaceuticals, Inc. shares in Q4 2014, an estimated $237K.
  • Baker Avenue Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2014 and held it in 1 quarter.
  • Baker Avenue Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $237K in Q3 2014.
  • 169 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2014.

Based on Baker Avenue Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.